EP0095944A2 — Anti-androgenic preparation for oral cavity administration
Assigned to Takeda Pharmaceutical Co Ltd · Expires 1983-12-07 · 42y expired
What this patent protects
A pharmaceutical composition, suitable for use in treating prostatomegaly, comprises an anti-androgenically active compound represented by the formula [1]: wherein the bond at the 10-position indicates a carbon-carbon single bond or a carbon-carbon double bond and A indicate…
USPTO Abstract
A pharmaceutical composition, suitable for use in treating prostatomegaly, comprises an anti-androgenically active compound represented by the formula [1]: wherein the bond at the 10-position indicates a carbon-carbon single bond or a carbon-carbon double bond and A indicates a hydrogen atom or an ether or ester residue, and other appropriate components so that the preparation is in the form of an administration unit which is intended to be placed in the oral cavity of a patient to enable the anti-androgenically active compound of formula [I] to be absorbed through the oral mucous membrane. The administration unit has a disintegration time of 30 minutes or longer.
Drugs covered by this patent
- Zovirax (ACYCLOVIR) · Ligand Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.